Cooperative Estrogen Replacement Therapy (CERT)

Cooperative Estrogen Replacement Therapy (CERT) is a NaProTechnology treatment that supports low estrogen during a woman's cycle. Dr. Thomas W. Hilgers developed it. Clinicians consider CERT when the body produces too little estrogen. Examples include poor cervical mucus and some forms of luteal phase deficiency, a weak phase after ovulation.¹

CERT differs from hormone therapy after menopause. It is intended for women of reproductive age who still have a cycle. Clinicians guide it with Peak Day charting and blood hormone tests. Cervical mucus develops as estrogen rises before Peak Day. For this reason, the mucus cycle is a direct sign of estrogen activity. Little or no mucus can be one clue that estrogen needs closer evaluation. Low estrogen before Peak Day can impair cervical mucus quality. It can also affect the endometrium, the lining of the uterus.²

As with CPRT, the word "cooperative" describes the design. Clinicians time estrogen support to work with the body's own cycle. The treating clinician chooses the drug, dose, route and timing. Each woman's chart and test results guide that choice. CERT uses isomolecular hormones. These hormones have the same chemical structure as the body's own estrogen (estradiol). This design fits the NaProTechnology aim of matching the body's natural hormone pattern.¹

CERT works within the wider NaProTechnology medical care system. Estrogen helps run the whole cycle, before and after Peak Day. It influences egg development, the readiness of the uterus for pregnancy, and how well the phase after ovulation works. CERT reflects a core NaProTechnology goal: to restore the body's own hormone production rather than bypass it. Options include transdermal estrogen, given through the skin, and other routes chosen for each woman.